Huntington's Disease Treatment Market Research Report: by drug type (tetrabenazinedeutetrabenazine, chlorpromazine and others), Treatment (symptomatic therapy, disease-modifying therapy), End-users (hospital and others) - Forecast Till 2030

Huntington's Disease Treatment Market Scenario:

Huntington’s Disease Treatment Market is expected to rise steadily at a CAGR of 42.3% during forecast period of 2020-2030.

Huntington’s Disease is a genetic disorder that causes degeneration of nerve cells in brain. The degeneration of brain cells controls movement, intellectual ability and behaviour of that person. This disease normally appears at the age of 30-50 and gets worsen within 10-25 years of time. Huntington’s disease is fatal and there is no cure for this disease.

The Huntington’s Disease Treatment Market is largely driven by factors such as increased adoption of novel therapeutics, increase in R&D activities, rise in target population and favourable government initiatives. The huntington’s disease pipeline will see the new development in coming years as the disease modifying drugs transforms the market landscape. Many key players in market are engaged in development of new drug products for the treatment of huntington disease. At present, more than 20 products are being studied for treatment for huntington’s disease in various stages of clinical trials.

However certain factors that can hamper the growth of this market in near future are lack of awareness regarding genetic disorders and alternative treatment plans. 

Segmentation:

Huntington’s Disease Treatment Market is segmented into drug type, treatment and end-users. On basis of drug type the Huntington’s Disease Treatment Market is segmented into tetrabenazine, deutetrabenazine, selective serotonin reuptake inhibitor (SSRI), chlorpromazine,haloperidol, risperidone, olanzapine, clozapine another drug type.Based on treatment the market is further segmented into two types such as symptomatic therapy and disease-modifying therapy.On basis of end-users the market is further segmented into hospital, clinics, retail pharmacies, online pharmacies and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Huntington’s Disease Treatment Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of traumatic brain injury market.  The European Huntington’s Disease Treatment Market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The Huntington’s Disease Treatment Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The huntington’s disease treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

Some of the key players in the Huntington’s Disease Treatment Market are Alnylam Pharmaceuticals Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer, Palobiofarma, Omeros Ipsen, Valeant Pharmaceuticals International Inc.

Regional Market Summary

Global Huntington’s Disease Treatment Market Share (%), by Region, 2017

Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon

Geographically, the America holds the highest market share for huntington’s disease treatment market and the reason being many market players are engaged in development of new drug product innovation. According to the survey carried out by one of the University of Sheffield, the estimated prevalence of huntington’s disease in North America, North Western Europe and Australia ranges from 5.96 to 13.7 cases per 100 000 population.

Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of targeted population, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region. 

The prevalence of huntington’s disease is significantly lower in Asian populations compared to Western Europe, North America and Australia.

The market in the Middle East & Africa is likely to account for the smallest share of the global huntington’s disease treatment.

Huntington’s Disease Treatment Market by Drug Type:

•      Tetrabenazine


•      Deutetrabenazine


•      Selective Serotonin Reuptake Inhibitor (SSRI)


•      Chlorpromazine


•      Haloperidol


•      Risperidone


•      Olanzapine


•      Clozapine


•      Other

Huntington’s Disease Treatment Market, by Treatment:

•      Symptomatic Therapy


•      Disease-Modifying Therapy

Huntington’s Disease Treatment Market, by End-Users:

•       Hospital


•       Clinics


•       Online Pharmacies


•       Retail Pharmacies


•       Others

Huntington’s Disease Treatment Market, by Region:

• Americas
  
  
  
  •  North America
    
    
    
    •     US
    
    
    •     Canada
    
    
    
    
  
  
  •  South America
  
  
  
  


• Europe
  
  
  
  •  Western Europe
    
    
    
    •   Germany
    
    
    •     France
    
    
    •   Italy
    
    
    •   Spain
    
    
    •   UK
    
    
    •   Rest of Western Europe
    
    
    
    
  
  
  •  Eastern Europe
  
  
  
  


• Asia Pacific
  
  
  
  •   Japan
  
  
  •   China
  
  
  •  India
  
  
  • Australia  
  
  
  • Republic of Korea 
  
  
  • Rest of Asia Pacific 
  
  
  
  


• The Middle East & Africa
  
  
  
  •   Middle East
  
  
  •   Africa
  
  
  
  

Huntington’s Disease Treatment Market Key Players:

•        Alnylam Pharmaceuticals Inc


•        AmpliPhi Biosciences Corp


•        Ceregene Inc


•        Lundbeck


•        Prana Biotechnology Limited


•        Teva Pharmaceutical Industries Ltd


•        Cortex Pharmaceuticals Inc


•        Vertex Pharmaceuticals Incorporated


•        Auspex Pharmaceuticals


•        SOM Biotech


•        GlaxoSmithKline


•        Siena Biotech


•        Raptor Pharmaceutical


•        Pfizer


•        Palobiofarma


•        Omeros


•        Ipsen


•        Valeant Pharmaceuticals International Inc

Intended Audience:

• Manufacturers and Suppliers


• Hospitals and Clinics


• Laboratories and Associations


• Research and Development (R&D) Companies


• Government research institutes


• Academic institutes and universities